Inspection Record

Central Illinois Compounding, Inc. dba Preckshot Professional Pharmacy — FDA 483 Findings

US FDAInspected 2018-05-22Published 2024-01-17 4 findingsEquipment and facilityOther quality systemAseptic processing and sterility assurance

Inspectors Robert J Ham · Tiara N Brown-CrosenThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Equipment and facility

Procedures for the cleaning and maintenance of equipment are deficient regarding the protection of clean equipment from contamination prior to use.

2Equipment and facility

The ISO-classified areas have difficult to clean, particle-generating, or visibly dirty equipment or surfaces.

3Other quality system

Your firm released drug product in which the strength differs from, or its purity or quality falls below, that which it purports or is represented to possess.

4Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

About this record

Extracted automatically from the document US FDA published on 2024-01-17. The source is available at the link above.

This is a record of that moment. Inspection findings are usually followed by the company's response and corrective action, but this page does not know how that turned out. Do not read it as the current state; check the regulator's official announcements for the latest status.

Translation and classification are automated and may differ in nuance from the source.

Central Illinois Compounding, Inc. dba Preckshot Professional Pharmacy company profile — full history US FDA documents, 2024 Go to Findings search